Clinical Trials Logo

Filter by:
NCT ID: NCT06243887 Not yet recruiting - Esophageal Diseases Clinical Trials

Implementing Enhanced Recovery After Surgery (ERAS) Protocol in Patients Undergoing Minimal Invasive Esophagectomy

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Detect impact of enhanced recovery after surgery (ERAS) on the outcomes of oesophageal surgery .

NCT ID: NCT06246396 Not yet recruiting - Clinical trials for Hypertension, Resistant to Conventional Therapy

Antihypertensive Mechanisms of Minocycline in Resistant Hypertension

Start date: April 1, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are: - To what extent does minocycline lower blood pressure and are these effects different across races? - Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these? Participants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.

NCT ID: NCT06247839 Not yet recruiting - Clinical trials for Major Depressive Disorder

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder

Start date: April 1, 2024
Phase: Phase 3
Study type: Interventional

This open-label functional Magnetic Resonance Imaging (fMRI) study will assess the effects of a single dose of psilocybin on rumination and the neural correlates of rumination in individuals with major depressive disorder.

NCT ID: NCT06248632 Not yet recruiting - Clinical trials for X-Linked Hypophosphatemic Rickets

Effect of Burosumab on the Inflammatory Profile of Patients With X-linked Hypophosphatemic Rickets FLAM-XLH

FLAM-XLH
Start date: April 1, 2024
Phase:
Study type: Observational

X-linked hypophosphataemia (XLH) is a rare genetic disorder associated with increased circulating levels of the hormone FGF23, most commonly through mutation of the PHEX gene. XLH is associated with a wide range of clinical manifestations in children and adults, all of which can impact on their health-related quality of life. Conventional treatment (or standard of care, SOC) consists of phosphate supplementation and active vitamin D analogues. The management of patients with XLH has been modified in France since 2018 with the authorisation of the anti-FGF23 antibody, burosumab, in paediatrics (and in 2020 in adults). A propensity for overweight/obesity has recently been demonstrated in these patients. Could extra-skeletal effects of FGF23, in particular on the inflammatory profile of patients, be responsible for these manifestations? Obesity has been associated with inflammation in other populations. In terms of inflammation, there is a close link between FGF23 and inflammation: inflammatory cytokines increase the production of FGF23, which in turn increases inflammation by stimulating the production of inflammatory cytokines. Osteoclastogenesis and inflammation are linked and inflammation has been shown to increase bone resorption. In a recent study, the investigators showed that osteoclastogenesis was significantly impaired in cells obtained from XLH patients compared with control patients, and that osteoclasts obtained from XLH children showed higher gene expression of inflammatory markers than controls. Interestingly, no difference was observed in circulating monocytic cells between the two patient subgroups, conservative treatment and burosumab, whereas the inflammatory profile at the end of osteoclastic differentiation was reduced in cells derived from patients receiving burosumab. The aim of this study is therefore to investigate the inflammatory profile of circulating monocytic cells on the day of burosumab injection (D0) and seven days later (peak effect of anti-FGF23).

NCT ID: NCT06249035 Not yet recruiting - Cardiac Arrest Clinical Trials

Feasibility of TEE During Cardiac Arrest in Dutch Emergency Departments

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The goal of this feasibility study is to learn if Dutch ED providers are able to use transesophageal echocardiography during cardiac arrest. The main question it aims to answer is: • are the ED providers able to determine the area of maximal compression of the heart using TEE

NCT ID: NCT06250036 Not yet recruiting - Clinical trials for Metastatic Gastric Cancer

Peri-operative Zimberelimab (Anti-PD-1) vs Zimberelimab in Combination With Domvanalimab (Anti-TIGIT) in Resectable Mismatch Repair Deficient/Micro-satellite Unstable Gastric and Gastro-oesophageal Junctional Adenocarcinoma (ZODIAC)

ZODIAC
Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

A phase II study of peri-operative anti-PD1 (Zimberelimab) +/- anti-TIGIT (Domvanalimab) in resectable mismatch repair deficient (MMRd)/ high micro-satellite instability (MSI-H) gastric/gastro-oesophageal junctional (GOJ) adenocarcinoma (AC)

NCT ID: NCT06252012 Not yet recruiting - Nurse's Role Clinical Trials

The Effect of Cervical Cancer Awareness Education Based on Mobile Application

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Cervical cancer is one of the most common cancer types affecting women in our country and in the world and causing morbidity. However, the availability of a vaccine for cervical cancer, preventable risk factors and early diagnosis tests offer a unique opportunity to reduce the rate of cervical cancer. In this context, there are studies showing that the practices developed by policies differ and that the classical health approach is insufficient. The effectiveness of the trainings given may vary according to time, place, trainer and personal characteristics of the individual. At the same time, in order to improve the attitudes and behaviours of individuals in terms of prevention and early diagnosis of cervical cancer, awareness of individuals about cervical cancer should be increased. In this way, women will have a say about their own health and their conscious participation in health care services will be realised. Therefore, the aim of this project is to apply cervical cancer awareness training to women and to examine its effect on women's cervical cancer prevention and early diagnosis behaviours. Original value; The fact that there is no mobile application developed for cervical cancer in Turkey reveals the national value of the research. In addition, the mobile application has international unique value as it is the first mobile application structured to provide awareness on cervical cancer prevention and early diagnosis behaviours. The project method was planned for the development and implementation of the mobile application programme. The research design will be a randomised controlled study. The 120 women who meet the inclusion criteria and who apply to more than one family health centre will be randomly assigned to the intervention and control groups. The effect of the mobile application programme on women's attitudes and behaviours towards cervical cancer prevention and early diagnosis will be evaluated at the 6th and 12th weeks. In the evaluation of the data, t-test for independent groups, anova and chi-square tests will be used to measure the effect of the intervention. Widespread effect; In this way, it is planned to reduce the time spent by professionals for care-related activities, to strengthen time management, to provide advantages and improvements in the performance of nurses in patient care management by using technological resources in the health care provided.

NCT ID: NCT06252961 Not yet recruiting - Loiasis Clinical Trials

A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects

STOP-FiLAR
Start date: April 1, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of the study is to evaluate the safety and efficacy of a 3- and 5-day course of levamisole (2.5 mg/kg) in management of loiasis microfilaremia.

NCT ID: NCT06254625 Not yet recruiting - Clinical trials for Diverticulitis, Colonic

Fecal Transplantation in Patients Colonic Diverticulitis

Start date: April 1, 2024
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to investigate the safety and effect of fecal microbiome transplantation (FMT) in patients with a former episode of acute colonic diverticulitis. The main question[s] it aims to answer are: - Is FMT in patients with a former episode of acute colonic diverticulitis a safe procedure without severe adverse events - What is the impact of FMT on patient-reported outcomes and re-admission rate Participants will be asked to: - to ingest either 25-30 capsules with FMT or placebo capsules - Fill-in GI-QLI questionnaire prior to treatment/placebo and 3 months post baseline - Fill-in eating habit questionnaire - deliver blood-and stool samples prior to treatment/placebo and 3 months post baseline - In both the treatment and placebo group 5 patients will be offered sigmoideoscopy for mucosal biopsies if it is more than 2 items]. If there is a comparison group: Researchers will compare [insert groups] to see if [insert effects]

NCT ID: NCT06255535 Not yet recruiting - Clinical trials for Autism Spectrum Disorder

pBFS Guided rTMS Over Cognitive Control Network for ASD

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The aim of this trial is to assess the efficacy and safety of precision neuromodulation for alleviating core symptoms in patients with autism spectrum disorder (ASD) who also have intellectual or developmental delay. The neuromodulation will be administered using intermittent theta burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex (DLPFC), guided by personalized Brain Functional Sector (pBFS) technology.